Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of VOB560 + MIK665 in relapsed/refractory hematologic malignancies
jRCT2041210091Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of VOB560 and S64315 in non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML) and multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Safety and tolerability. Started Oct 2021; status: completed.
02
Drugs
VOB560S64315
03
Conditions
non-Hodgkin lymphoma (NHL)acute myeloid leukemia (AML)multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2041210091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210091.